Response  ||| S:0 E:9 ||| NN
predictive  ||| S:9 E:20 ||| JJ
biomarkers  ||| S:20 E:31 ||| NN
to  ||| S:31 E:34 ||| TO
targeted  ||| S:34 E:43 ||| JJ
therapies  ||| S:43 E:53 ||| NNS
in  ||| S:53 E:56 ||| IN
oncology  ||| S:56 E:65 ||| JJ
Cancer  ||| S:65 E:72 ||| NNP
kills  ||| S:72 E:78 ||| VBZ
147,500  ||| S:78 E:86 ||| CD
people  ||| S:86 E:93 ||| NNS
each  ||| S:93 E:98 ||| DT
year  ||| S:98 E:103 ||| NN
in  ||| S:103 E:106 ||| IN
France ||| S:106 E:112 ||| NNP
.  ||| S:112 E:114 ||| .
The  ||| S:114 E:118 ||| DT
development  ||| S:118 E:130 ||| NN
of  ||| S:130 E:133 ||| IN
personalized  ||| S:133 E:146 ||| JJ
therapies  ||| S:146 E:156 ||| NNS
and  ||| S:156 E:160 ||| CC
more  ||| S:160 E:165 ||| RBR
recently  ||| S:165 E:174 ||| RB
theranostics ||| S:174 E:186 ||| JJ
,  ||| S:186 E:188 ||| ,
completely  ||| S:188 E:199 ||| RB
changed  ||| S:199 E:207 ||| VBN
the  ||| S:207 E:211 ||| DT
biological  ||| S:211 E:222 ||| JJ
approach  ||| S:222 E:231 ||| NN
to  ||| S:231 E:234 ||| TO
this  ||| S:234 E:239 ||| DT
disease ||| S:239 E:246 ||| NN
.  ||| S:246 E:248 ||| .
Thus ||| S:248 E:252 ||| RB
,  ||| S:252 E:254 ||| ,
the  ||| S:254 E:258 ||| DT
already  ||| S:258 E:266 ||| RB
well-known  ||| S:266 E:277 ||| JJ
but  ||| S:277 E:281 ||| CC
sparsely  ||| S:281 E:290 ||| RB
specific  ||| S:290 E:299 ||| JJ
serum  ||| S:299 E:305 ||| JJ
markers  ||| S:305 E:313 ||| NNS
are  ||| S:313 E:317 ||| VBP
being  ||| S:317 E:323 ||| VBG
replaced  ||| S:323 E:332 ||| VBN
by  ||| S:332 E:335 ||| IN
new  ||| S:335 E:339 ||| JJ
tumor  ||| S:339 E:345 ||| NN
markers ||| S:345 E:352 ||| NN
,  ||| S:352 E:354 ||| ,
predictive  ||| S:354 E:365 ||| JJ
of  ||| S:365 E:368 ||| IN
resistance  ||| S:368 E:379 ||| NN
or  ||| S:379 E:382 ||| CC
response  ||| S:382 E:391 ||| NN
to  ||| S:391 E:394 ||| TO
targeted  ||| S:394 E:403 ||| JJ
therapies ||| S:403 E:412 ||| NNS
.  ||| S:412 E:414 ||| .
The  ||| S:414 E:418 ||| DT
study  ||| S:418 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
these  ||| S:427 E:433 ||| DT
biomarkers  ||| S:433 E:444 ||| NN
is  ||| S:444 E:447 ||| VBZ
performed  ||| S:447 E:457 ||| VBN
by  ||| S:457 E:460 ||| IN
different  ||| S:460 E:470 ||| JJ
technical  ||| S:470 E:480 ||| JJ
approaches ||| S:480 E:490 ||| NNS
,  ||| S:490 E:492 ||| ,
which  ||| S:492 E:498 ||| WDT
are  ||| S:498 E:502 ||| VBP
essentially  ||| S:502 E:514 ||| RB
based  ||| S:514 E:520 ||| VBN
molecular  ||| S:520 E:530 ||| JJ
biology  ||| S:530 E:538 ||| NN
assays ||| S:538 E:544 ||| NN
.  ||| S:544 E:546 ||| .
These  ||| S:546 E:552 ||| DT
determinations  ||| S:552 E:567 ||| NNS
are  ||| S:567 E:571 ||| VBP
assessed  ||| S:571 E:580 ||| VBN
in  ||| S:580 E:583 ||| IN
France  ||| S:583 E:590 ||| NNP
within  ||| S:590 E:597 ||| IN
the  ||| S:597 E:601 ||| DT
28  ||| S:601 E:604 ||| CD
molecular  ||| S:604 E:614 ||| JJ
tumor  ||| S:614 E:620 ||| NN
genetics  ||| S:620 E:629 ||| NNS
platforms  ||| S:629 E:639 ||| VBP
approved  ||| S:639 E:648 ||| VBN
by  ||| S:648 E:651 ||| IN
French  ||| S:651 E:658 ||| NNP
National  ||| S:658 E:667 ||| NNP
Cancer  ||| S:667 E:674 ||| NNP
Institute  ||| S:674 E:684 ||| NNP
( ||| S:684 E:685 ||| -LRB-
INCa ||| S:685 E:689 ||| NNP
) ||| S:689 E:690 ||| -RRB-
.  ||| S:690 E:692 ||| .
The  ||| S:692 E:696 ||| DT
most  ||| S:696 E:701 ||| RBS
commonly  ||| S:701 E:710 ||| RB
used  ||| S:710 E:715 ||| VBN
assays  ||| S:715 E:722 ||| VBN
for  ||| S:722 E:726 ||| IN
this  ||| S:726 E:731 ||| DT
type  ||| S:731 E:736 ||| NN
of  ||| S:736 E:739 ||| IN
molecular  ||| S:739 E:749 ||| JJ
diagnostics ||| S:749 E:760 ||| NNS
,  ||| S:760 E:762 ||| ,
such  ||| S:762 E:767 ||| JJ
as  ||| S:767 E:770 ||| IN
real-time  ||| S:770 E:780 ||| JJ
PCR ||| S:780 E:783 ||| NNP
,  ||| S:783 E:785 ||| ,
the  ||| S:785 E:789 ||| DT
sequencing ||| S:789 E:799 ||| NN
,  ||| S:799 E:801 ||| ,
immunohistochemistry ||| S:801 E:821 ||| NN
,  ||| S:821 E:823 ||| ,
FISH  ||| S:823 E:828 ||| NNP
or  ||| S:828 E:831 ||| CC
CISH ||| S:831 E:835 ||| NNP
,  ||| S:835 E:837 ||| ,
are  ||| S:837 E:841 ||| VBP
relatively  ||| S:841 E:852 ||| RB
difficult  ||| S:852 E:862 ||| JJ
because  ||| S:862 E:870 ||| IN
most  ||| S:870 E:875 ||| JJS
of  ||| S:875 E:878 ||| IN
them  ||| S:878 E:883 ||| PRP
are  ||| S:883 E:887 ||| VBP
based  ||| S:887 E:893 ||| VBN
on  ||| S:893 E:896 ||| IN
the  ||| S:896 E:900 ||| DT
use  ||| S:900 E:904 ||| NN
of  ||| S:904 E:907 ||| IN
formalin  ||| S:907 E:916 ||| FW
fixed  ||| S:916 E:922 ||| FW
paraffin  ||| S:922 E:931 ||| FW
embedded  ||| S:931 E:940 ||| FW
tumor  ||| S:940 E:946 ||| FW
tissues ||| S:946 E:953 ||| FW
.  ||| S:953 E:955 ||| .
This  ||| S:955 E:960 ||| DT
paper  ||| S:960 E:966 ||| NN
provides  ||| S:966 E:975 ||| VBZ
a  ||| S:975 E:977 ||| DT
synthesis  ||| S:977 E:987 ||| NN
of  ||| S:987 E:990 ||| IN
validated  ||| S:990 E:1000 ||| JJ
theranostic  ||| S:1000 E:1012 ||| JJ
biomarkers  ||| S:1012 E:1023 ||| NN
and  ||| S:1023 E:1027 ||| CC
the  ||| S:1027 E:1031 ||| DT
most  ||| S:1031 E:1036 ||| RBS
used  ||| S:1036 E:1041 ||| VBN
diagnostic  ||| S:1041 E:1052 ||| JJ
methods ||| S:1052 E:1059 ||| NNS
,  ||| S:1059 E:1061 ||| ,
but  ||| S:1061 E:1065 ||| CC
also  ||| S:1065 E:1070 ||| RB
draw  ||| S:1070 E:1075 ||| VB
a  ||| S:1075 E:1077 ||| DT
point  ||| S:1077 E:1083 ||| NN
on  ||| S:1083 E:1086 ||| IN
the  ||| S:1086 E:1090 ||| DT
best  ||| S:1090 E:1095 ||| RBS
incoming  ||| S:1095 E:1104 ||| JJ
biomarkers  ||| S:1104 E:1115 ||| JJ
candidates  ||| S:1115 E:1126 ||| NNS
and  ||| S:1126 E:1130 ||| CC
assays  ||| S:1130 E:1137 ||| NN
in  ||| S:1137 E:1140 ||| IN
close  ||| S:1140 E:1146 ||| JJ
development  ||| S:1146 E:1158 ||| NN
using  ||| S:1158 E:1164 ||| VBG
liquid  ||| S:1164 E:1171 ||| JJ
biopsies ||| S:1171 E:1179 ||| NNS
.  ||| S:1179 E:1181 ||| .
